June 16th, 2020 | 06:30 CEST
Gilead, Teva, XPhyto - Global marketing potential
The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.
time to read: 2 minutes
|
Author:
Mario Hose
ISIN:
CA98421R1055 , US8816242098 , US3755581036
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Thin Film Solutions for a Mass Market
XPhyto from Canada announced yesterday that its German subsidiary Vektor Pharma TF GmbH has successfully incorporated peptide biosensors into the group's oral dissolvable thin film (ODF) technology. Together with its partner 3a-Diagnostics GmbH, the company is now developing pathogen-specific ODF biosensors for infectious diseases, including pandemic threats, the company announced.
"Successful incorporation of 3a's peptide biosensors into Vektor's ODF platform represents a significant technical milestone on the pathway to commercialization," Hugh Rogers, XPhyto CEO said in a statement. "This was a critical step that unlocks a pipeline of potential biosensor screening products."
3a biosensor screening tests have been developed for bacterial and viral infectious diseases, including influenza A, scarlet fever and periodontitis. The market is therefore large and further pandemic-focused biosensors are planned and developed, especially for coronavirus, swine flu and avian flu, according to the announcement. The partnership at product level therefore has potential. The market value of XPhyto is EUR 115.1 million.
Products for the Chinese market
Teva recently announced that the Chinese Food and Drug Administration has approved Austedo for the treatment of chorea associated with Huntington's disease and late dyskinesia in adults. According to the announcement, the company will independently market the drug Austedo in China. This follows the launch of the specialty drug Treanda on the Chinese market.
"We look forward to bringing more of the essential medicines in our portfolio to patients in China, and to fuel organic growth and expand our presence in this important market," said Gianfranco Nazzi of Teva, who is responsible for international markets. The market value of the company is around EUR 10.9 billion.
Licensing for 127 countries
Last week Gilead signed a license agreement with Dr. Reddy's Laboratories Ltd. for the registration, manufacture and sale of the antiviral drug Remdesivir. The product Remdesivir became known because it can be used to treat the current coronavirus. The contract covers a total of 127 countries, but an official approval for the marketing of Remdesivir in the respective country still has to be obtained from Dr. Reddy's.
In May 2020, the US Food and Drug Administration (FDA) granted emergency use authorization for Gilead's antiviral drug Remdesivir for the treatment of Covid-19. Under the non-exclusive license agreement, Dr. Reddy's will receive a technology transfer from Gilead for the manufacture of Remdesivir. Gilead's most recent market capitalization was approximately EUR 82.4 billion and this makes the company one of the heavyweights in the industry.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.